eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Amgen, Inc. - Comment

Amgen, Inc. - Comment

Document ID: FDA-2009-D-0539-0011
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: February 01 2010, at 05:28 PM Eastern Standard Time
Date Posted: February 2 2010, at 12:00 AM Eastern Standard Time
Comment Start Date: December 4 2009, at 12:00 AM Eastern Standard Time
Comment Due Date: February 2 2010, at 11:59 PM Eastern Standard Time
Tracking Number: 80a8934f
View Document:  View as format xml

View Comment

Amgen thanks the FDA for the opportunity to submit comments on the Draft Guidance for Industry on Assay Development for Immunogenicity Testing of Therapeutic Proteins; Availability (Document ID FDA-2009-D-0539-0001)

Attachments:

Amgen, Inc. - Comment

Title:
Amgen, Inc. - Comment

View Attachment: View as format pdf

Related Comments

    View All
Total: 13
Novo Nordisk Inc. - Comment
Public Submission    Posted: 01/27/2010     ID: FDA-2009-D-0539-0004

Feb 02,2010 11:59 PM ET
MedImmune - Comment
Public Submission    Posted: 02/01/2010     ID: FDA-2009-D-0539-0005

Feb 02,2010 11:59 PM ET
Covance Laboratories Inc. - Comment
Public Submission    Posted: 02/02/2010     ID: FDA-2009-D-0539-0010

Feb 02,2010 11:59 PM ET
Amgen, Inc. - Comment
Public Submission    Posted: 02/02/2010     ID: FDA-2009-D-0539-0011

Feb 02,2010 11:59 PM ET
Facet Biotech - Comment
Public Submission    Posted: 02/02/2010     ID: FDA-2009-D-0539-0015

Feb 02,2010 11:59 PM ET